Global Drugs for Xerostomia Market Research Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Drugs for Xerostomia Market Research Report 2024
Drugs for Xerostomia include prescription and over-the-counter mouthwashes, artificial saliva or humectants to moisturize the mouth, mouthwashes specially for dry mouth, especially those containing xylitol
According to Mr Accuracy reports new survey, global Drugs for Xerostomia market is projected to reach US$ 907.1 million in 2029, increasing from US$ 714 million in 2022, with the CAGR of 3.5% during the period of 2024 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Drugs for Xerostomia market research.
Xerostomia, commonly referred to as "xerostomia syndrome," is the result of reduced or absent saliva flow, resulting in dry mucous membranes. Increase in radiation therapy and chemotherapy may lead to increased incidence of xerostomia, which is expected to primarily drive the xerostomia treatment market. Other factors driving the market growth include growing geriatric population base; rising prevalence of diseases such as HIV, diabetes, and Alzheimer's disease.
Furthermore, the geriatric population is expected to have a significant impact on the studied market. For example, according to the 2022 World Population Prospects, the global population aged 65 and over will be 771 million in 2022, and it is expected to reach 994 million by 2030 and 1.6 billion by 2050. Older adults often experience dry mouth, which is often associated with reduced salivary gland activity. Medication use, chronic disease, and radiation therapy to the head and neck area have all been cited as causes of xerostomia in older adults.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Drugs for Xerostomia market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Concordia
AMICI
Aurobindo Pharma Ltd
Impax Labs
Lannett Co Inc
Padagis Us
Amneal Pharmaceuticals Pvt. Ltd.
Bausch Health Companies Inc.
GSK
Jazz Pharmaceuticals plc
Mission Pharmacal Company
OraCoat
Cumberland Pharmaceuticals, Inc.
Fleet, C.B., Company
Parnell Pharmaceuticals, Inc
Clinigen
Sun Pharm
Segment by Type
Spray
Oral Liquid
Buccal Tablet
Mouth Wash
Supermarket
Hospital
Other
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Drugs for Xerostomia report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source
According to Mr Accuracy reports new survey, global Drugs for Xerostomia market is projected to reach US$ 907.1 million in 2029, increasing from US$ 714 million in 2022, with the CAGR of 3.5% during the period of 2024 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Drugs for Xerostomia market research.
Xerostomia, commonly referred to as "xerostomia syndrome," is the result of reduced or absent saliva flow, resulting in dry mucous membranes. Increase in radiation therapy and chemotherapy may lead to increased incidence of xerostomia, which is expected to primarily drive the xerostomia treatment market. Other factors driving the market growth include growing geriatric population base; rising prevalence of diseases such as HIV, diabetes, and Alzheimer's disease.
Furthermore, the geriatric population is expected to have a significant impact on the studied market. For example, according to the 2022 World Population Prospects, the global population aged 65 and over will be 771 million in 2022, and it is expected to reach 994 million by 2030 and 1.6 billion by 2050. Older adults often experience dry mouth, which is often associated with reduced salivary gland activity. Medication use, chronic disease, and radiation therapy to the head and neck area have all been cited as causes of xerostomia in older adults.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Drugs for Xerostomia market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Concordia
AMICI
Aurobindo Pharma Ltd
Impax Labs
Lannett Co Inc
Padagis Us
Amneal Pharmaceuticals Pvt. Ltd.
Bausch Health Companies Inc.
GSK
Jazz Pharmaceuticals plc
Mission Pharmacal Company
OraCoat
Cumberland Pharmaceuticals, Inc.
Fleet, C.B., Company
Parnell Pharmaceuticals, Inc
Clinigen
Sun Pharm
Segment by Type
Spray
Oral Liquid
Buccal Tablet
Mouth Wash
Segment by Application
Supermarket
Hospital
Other
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Drugs for Xerostomia report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices